PE20091693A1 - Antagonista del receptor 2 activado con proteasa - Google Patents
Antagonista del receptor 2 activado con proteasaInfo
- Publication number
- PE20091693A1 PE20091693A1 PE2009000397A PE2009000397A PE20091693A1 PE 20091693 A1 PE20091693 A1 PE 20091693A1 PE 2009000397 A PE2009000397 A PE 2009000397A PE 2009000397 A PE2009000397 A PE 2009000397A PE 20091693 A1 PE20091693 A1 PE 20091693A1
- Authority
- PE
- Peru
- Prior art keywords
- antagonist
- protease
- par2
- activated receptor
- antibody
- Prior art date
Links
- 229940118430 Protease-activated receptor-2 antagonist Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 1
- 208000006820 Arthralgia Diseases 0.000 abstract 1
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010017076 Fracture Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 abstract 1
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 abstract 1
- 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102100036863 Solute carrier family 52, riboflavin transporter, member 1 Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3790808P | 2008-03-19 | 2008-03-19 | |
| US11915508P | 2008-12-02 | 2008-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091693A1 true PE20091693A1 (es) | 2009-11-16 |
Family
ID=40718925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000397A PE20091693A1 (es) | 2008-03-19 | 2009-03-17 | Antagonista del receptor 2 activado con proteasa |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR070911A1 (zh) |
| CL (1) | CL2009000660A1 (zh) |
| PE (1) | PE20091693A1 (zh) |
| TW (1) | TW201002345A (zh) |
| UY (1) | UY31723A (zh) |
| WO (1) | WO2009117481A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214655B2 (en) * | 2001-05-21 | 2007-05-08 | Johnson & Johnson Consumer Companies, Inc. | Peptides and the use thereof in darkening the skin |
| US7888482B2 (en) | 2006-02-10 | 2011-02-15 | Amgen Inc. | Antibodies that bind PAR-2 |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| US9333152B2 (en) | 2011-11-04 | 2016-05-10 | Lipotec, S.A. | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
| EP3049418A1 (en) | 2013-09-25 | 2016-08-03 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
| US20160000791A1 (en) | 2014-07-07 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Par1 modulation to alter myelination |
| US20190298743A1 (en) * | 2016-05-20 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Treatment of pain |
| US20190201454A1 (en) * | 2016-06-23 | 2019-07-04 | Mayo Foundation For Medical Education And Research | Par2 modulation to alter myelination |
| CR20190417A (es) | 2017-03-16 | 2019-12-06 | Medimmune Ltd | Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996023225A1 (en) * | 1995-01-25 | 1996-08-01 | Cor Therapeutics, Inc. | Recombinant c140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
| US5629174A (en) * | 1993-07-26 | 1997-05-13 | Cor Therapeutics, Inc. | Recombinant C140 receptor |
| US20090035315A1 (en) * | 2004-06-17 | 2009-02-05 | Stephan Christgau | Method of Improving Treatments in Rheumatic and Arthritic Diseases |
-
2009
- 2009-03-16 AR ARP090100937A patent/AR070911A1/es unknown
- 2009-03-17 PE PE2009000397A patent/PE20091693A1/es not_active Application Discontinuation
- 2009-03-18 WO PCT/US2009/037504 patent/WO2009117481A1/en not_active Ceased
- 2009-03-18 CL CL2009000660A patent/CL2009000660A1/es unknown
- 2009-03-18 TW TW098108692A patent/TW201002345A/zh unknown
- 2009-03-19 UY UY0001031723A patent/UY31723A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2009000660A1 (es) | 2010-04-16 |
| AR070911A1 (es) | 2010-05-12 |
| TW201002345A (en) | 2010-01-16 |
| WO2009117481A1 (en) | 2009-09-24 |
| UY31723A (es) | 2009-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091693A1 (es) | Antagonista del receptor 2 activado con proteasa | |
| PE20121563A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
| NI200800284A (es) | Composiciones farmacéuticas de antagonistas del anticuerpo anti-cd40 | |
| MX2012004035A (es) | Anticuerpos neutralizantes anti-ngf humanos como inhibidores selectivos de la trayectoria ngf. | |
| CL2013003214A1 (es) | Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol. | |
| EA200870425A1 (ru) | Применение агонистов рецептора grp119 для повышения костной массы и для лечения остеопороза и связанной с ними комбинированной терапии | |
| NO2017019I1 (no) | Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav | |
| CY1123240T1 (el) | Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει | |
| CL2007002492A1 (es) | Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras. | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| BR112017022772A2 (pt) | métodos para tratar ou prevenir cefaleia de enxaqueca | |
| MX2022005330A (es) | Moleculas de union multiespecificas con scfv en el extremo nterminal. | |
| CL2008003694A1 (es) | Compuestos derivados de heterociclo-2-carboxamida sustituida; composicion farmaceutica; combinacion farmaceutica; y su uso como inhibidores de dipeptidil peptidasa iv (dpp-iv) en el tratamiento del asma, epoc y rinitis alergica. | |
| EA201101475A1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
| EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
| NO20092637L (no) | Fremgangsmater for behandling | |
| DOP2009000281A (es) | Moleculas pequeñas que contienen boro | |
| CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
| PA8659301A1 (es) | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentracion sanguinea de glp-1 | |
| EA201200204A1 (ru) | Содержащая антитело к her2 композиция для подкожного введения | |
| ECSP10010446A (es) | Uso de ranolazina para el tratamiento del dolor | |
| CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
| CL2009000368A1 (es) | 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3. | |
| UY30479A1 (es) | Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4 | |
| EA201201457A1 (ru) | Органические композиции для лечения заболеваний, связанных с бета-субъединицей эпителиальных натриевых каналов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |